Cargando…

Clinical, Functional, and Economic Ramifications of Early Nonresponse to Antipsychotics in the Naturalistic Treatment of Schizophrenia

Objective: Early nonresponse to antipsychotics appears to predict subsequent nonresponse to treatment when assessed in randomized controlled trials of predominately acute inpatients treated for schizophrenia. This study assessed the predictive accuracy of early nonresponse to treatment and its clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ascher-Svanum, Haya, Nyhuis, Allen W., Faries, Douglas E., Kinon, Bruce J., Baker, Robert W., Shekhar, Anantha
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2008
Materias:	Regular Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2632496/ https://www.ncbi.nlm.nih.gov/pubmed/18156640 http://dx.doi.org/10.1093/schbul/sbm134

Ejemplares similares

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
por: Faries, Douglas E, et al.
Publicado: (2009)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
por: Nyhuis, Allen W, et al.
Publicado: (2010)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
por: Faries, Douglas, et al.
Publicado: (2012)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
por: Faries, Douglas E, et al.
Publicado: (2009)

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2005)

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2004)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
por: Ye, Wenyu, et al.
Publicado: (2012)

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
por: Chen, Lei, et al.
Publicado: (2013)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia
por: Liu-Seifert, Hong, et al.
Publicado: (2007)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
por: Peng, Xiaomei, et al.
Publicado: (2011)

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
por: Peng, Xiaomei, et al.
Publicado: (2011)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2012)

The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy
por: Montgomery, William, et al.
Publicado: (2013)

Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
por: Olfson, Mark, et al.
Publicado: (2007)

Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia
por: Ruberg, Stephen J, et al.
Publicado: (2011)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
por: Ye, Wenyu, et al.
Publicado: (2011)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation
por: Matza, Louis S, et al.
Publicado: (2012)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
por: Ye, Wenyu, et al.
Publicado: (2012)

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
por: Stauffer, Virginia, et al.
Publicado: (2009)

The longitudinal interplay between negative and positive symptom trajectories in patients under antipsychotic treatment: a post hoc analysis of data from a randomized, 1-year pragmatic trial
por: Chen, Lei, et al.
Publicado: (2013)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
por: Cuyún Carter, Gebra B, et al.
Publicado: (2011)

Costs of treating patients with schizophrenia who have illness-related crisis events
por: Zhu, Baojin, et al.
Publicado: (2008)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Ye, Wenyu, et al.
Publicado: (2012)

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
por: Haynes, Virginia S, et al.
Publicado: (2012)

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
por: Shi, Lizheng, et al.
Publicado: (2009)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2010)

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial
por: Chen, Lei, et al.
Publicado: (2011)

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
por: Furiak, Nicolas M, et al.
Publicado: (2009)

Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA)
por: Egerton, Alice, et al.
Publicado: (2020)

Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence
por: Kelin, Katarina, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0q0j31d4hapu2fqvh7n9ism7in